CS MEDICA Breaks New Ground in Australia with Registration of CANNASEN® Pain Patch and Launch of its Cosmetic Products.
CS MEDICA marks a significant milestone by introducing its medical device and two cosmetic products, underscoring its commitment to expanding global healthcare solutions.
CS MEDICA A/S ("CS MEDICA" or the "Company"), a MedTech company that focuses on treating pain, autoimmune diseases, and stress-related disorders with therapeutic Cannabis Sativa L./CBD, proudly announces its successful registration of the Pain Patch in Australia, along with an approval on two cosmetic products, the Anti-Hair Loss Serum and PSO+Atopic Skin Relief Lotion.
The journey to this achievement highlights the complexities and time-intensive nature of launching innovative healthcare products in new markets. The process involved resubmitting and aligning the products with the Therapeutic Goods Administration of Australia compliance requirements.
Lone Henriksen, CEO of CS MEDICA, reflects on this journey: "We are proud that we have managed to adapt and remain compliant and relevant for the market. It's a testament to our team's resilience and commitment. The registration of the CANNASEN® Pain Patch, the first substance-based medical device with Cannabis Sativa L in Australia, marks a significant milestone for us. It demonstrates our ability to navigate complex regulatory landscapes."
The company's launch in Australia for the cosmetic products and pain patch is carded in the second quarter of 2024. Five other products are in the pipeline of registration and could potentially be launched at the same time as our initial three approvals. Expected presales from major pharmacy buying groups across Australia may exceed manufacturing MOQs, which leads to a request for co-branded CANNASEN® packaging. The anticipated delivery of these orders is a step forward in establishing CS MEDICA's presence in the Oceanic Region.
Jakob Gajadhar, Director of Icon Medipharm, who is the sponsor of our Pain Patch, expressed enthusiasm: "We are excited to have partnered with CANNORDIC, their understanding of not only adapting to the registration process but also adjusting the brand to meet our local market requirements while staying brand consistent is commendable. Their products are effective, safe and of high quality, manufactured in Europe."
Dedicated to improving people's quality of life, the company's purpose is to drive change to treat autoimmune and stress-related diseases, built upon our knowledge of the endocannabinoid system and our experience in the pharmaceutical industry. The expansion into the Australian market indicates CS MEDICA's commitment to adapting to different market requirements, ensuring their innovative products are compliant, tailored, and accessible to local needs and preferences. The value of the first trance of the order accumulates to DKK 1 mio.
For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/
CS MEDICA is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and operating within the pharmaceutical industry. The company combines science and nature with the purpose of creating over-the-counter treatments to fight autoimmune and stress-related diseases, built upon our knowledge of the endocannabinoid system, patients' needs, and our experience in the pharmaceutical industry. We do so by pioneering scientific breakthroughs, expanding access to our treatments, understanding patients globally, and working to prevent the pain caused by the diseases we treat.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.
Tags: